Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233635 · ClinicalTrials.gov registry record · Phase 4
Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
A Phase 4 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 4
- Development phase
- 228
- Enrollment target
NCT01233635 is a Phase 4 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 228 participants.
The verdict
NCT01233635, a Phase 4 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 228 participants
- Enrollment target
Study Summary
In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interaction in secondary AF prevention. We have 3 specific aims: 1. To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence. 2. To test the hypothesis that the incidence of AF recurrence in the absence of RAAS inhibition therapy is higher among patients with the D allele. 3. To explore the hypothesis that RAAS inhibition therapy is more effective for preventing AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
Interventions
- OTHER no drug
- DRUG start cozaar
- DRUG continue cozaar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233635
The ClinicalTrials.gov registry entry for NCT01233635 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which no drug is the first listed.
NCT01233635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233635 about?
NCT01233635 is a clinical study titled "Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)". In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interaction in secondary AF prevention. We have 3 specific aims: 1. To confirm that RAAS inhibition therap...
What is the current status of trial NCT01233635?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 228 participants. The study started on 2005-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT01233635?
The interventions under investigation include: no drug (OTHER), start cozaar (DRUG), continue cozaar (DRUG).
Who is sponsoring clinical trial NCT01233635?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.